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erative and is a disease of advancing age (4). On the other 
hand, rheumatic heart disease and infective endocarditis re-
main endemic in developing countries, inflicting VHD in young 
patients (5). This difference in clinical profile of patients could 
affect their postoperative outcomes as well. The objective 
of this study was to test and compare the predictive perfor-
mance of additive EuroSCORE (AES), logistic EuroSCORE (LES), 
EuroSCORE II and STS scoring system in Pakistani patients un-
dergoing valvular surgery.
Patients and Methods
Retrospective data were extracted from the prospectively 
collected cardiothoracic database of the Aga Khan University 
Hospital. A total of 576 patients who underwent valvular heart 
surgery between January 2006 and July 2013 were included. 
We included mitral valve replacement (MVR), aortic valve 
replacement (AVR), double valve replacement (DVR), CABG + 
MVR and CABG + AVR patients. STS calculator does not code 
for DVR, therefore 490 patients were analyzed for this sub-
group. Thirty-day mortality was taken as the primary outcome 
(hospital mortality or death within 30 days postoperatively). 
The data set was eventually imported and analyzed using 
SPSS version 19 software (SPSS, Inc., Chicago, IL, USA).
LES was calculated for each patient based on the original 
EuroSCORE criteria by running a syntax code incorporating the 
regression coefficients and intercept developed by EuroSCORE. 
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ABSTRACT
Background: This is a validation study comparing the European System for Cardiac Operative Risk Evaluation 
(EuroSCORE) II with the previous additive (AES) and logistic EuroSCORE (LES) and the Society of Thoracic Surgeons’ 
(STS) risk prediction algorithm, for patients undergoing valve replacement with or without bypass in Pakistan.
Patients and Methods: Clinical data of 576 patients undergoing valve replacement surgery between 2006 and 
2013 were retrospectively collected and individual expected risks of death were calculated by all four risk predic-
tion algorithms. Performance of these risk algorithms was evaluated in terms of discrimination and calibration.
Results: There were 28 deaths (4.8%) among 576 patients, which was lower than the predicted mortality of 5.16%, 
6.96% and 4.94% by AES, LES and EuroSCORE II but was higher than 2.13% predicted by STS scoring system. For 
single and double valve replacement procedures, EuroSCORE II was the best predictor of mortality with highest 
Hosmer and Lemmeshow test (H-L) p value (0.346 to 0.689) and area under the receiver operating characteristic 
(ROC) curve (0.637 to 0.898). For valve plus concomitant coronary artery bypass grafting (CABG) patients actual 
mortality was 1.88%. STS calculator came out to be the best predictor of mortality for this subgroup with H-L 
p value (0.480 to 0.884) and ROC (0.657 to 0.775).
Conclusions: For Pakistani population EuroSCORE II is an accurate predictor for individual operative risk in 
patients undergoing isolated valve surgery, whereas STS performs better in the valve plus CABG group.
Keywords: Aortic, EuroSCORE, Mitral, Pakistan, Society of Thoracic Surgeons, Valve
Introduction
Risk prediction models play an important role in current 
cardiac surgical practice. Such models are useful in surgical 
decision-making, preoperative patient education and consent 
and quality assurance measures (1). Several tools have been 
developed in recent years, and among them the Society of 
Thoracic Surgeons� (STS) mortality risk score and the European 
System for Cardiac Operative Risk Evaluation (EuroSCORE) 
scoring system have gained widest popularity (2, 3).
These models have been developed and validated in a sur-
gical population composed mainly of those undergoing coro-
nary artery bypass grafting (CABG). However, valvular heart 
disease (VHD) comprises a unique subset, with etiologies that 
are different in developed and developing countries. Most 
valvular pathology in industrialized countries is now degen-
Accepted: July 25, 2014
Published online: September 24, 2014
Corresponding author:
Hasanat Sharif
Department of Cardiothoracic Surgery
Private wing 2nd floor
Aga Khan University Hospital
Karachi 74800, Pakistan
hasanat.sharif@aku.edu
EuroSCORE vs. STS score54 
© 2014 The Authors. Published by Wichtig Publishing
An individual score for the additive model was also calculated 
by a simple additive SPSS syntax. The EuroSCORE II and STS 
risk score were calculated with free online calculators available 
at http://www.euroscore.org and http://209.220.160.181/ 
STSWebRiskCalc261/de.aspx, respectively. The calculated score 
corresponds to the individual risk of death in the 30-day post-
operative period (predicted mortality).
Patient demographics are presented as percentages for 
discrete variables and mean (_standard deviation) for contin-
uous variables. Thirty-day mortality was taken as the primary 
outcome (actual mortality) and determined for the overall 
patient population, and trends in actual mortality were an-
alyzed across the entire risk spectrum. Performance of the 
models was also assessed by comparing the observed and 
expected mortality in quintiles of risk.
The discriminatory power of the models was assessed us-
ing the area under the receiver operating characteristic (ROC) 
curve with 95% confidence intervals; an area of 0.5 indicates 
no predictive ability, whereas an area of 1.0 represents perfect 
discrimination (6). Model calibration (the degree to which ob-
served outcomes are similar to the predicted outcomes from 
the model across patients) of AES, LES, EuroSCORE II and STS 
was examined by comparing average observed and predicted 
values within each of 10 equal-sized subgroups arranged in 
increasing order of patient risk. To evaluate model calibra-
tion, the Hosmer-Lemeshow test for the lack of “goodness 
of fit” was applied and graphically represented by a calibra-
tion plot. The smooth curve in a calibration plot reflects the 
nonparametric relationship between observed and predicted 
risk mortality. The straight dotted line through the origin of a 
calibration plot represents perfect calibration. Hosmer-Leme-
show p values above 0.05 indicate a well-calibrated model for 
the study population in question (7).
Results
The study population included 576 patients eligible for cal-
culation of EuroSCORE and 490 patients for STS risk score as 
it does not stand valid for DVRs. Mean age was 47.36 ± 15.47 
years with female population being 46.53%. Table I pres-
TABLE I - Prevalence of risk factors in study population
EuroSCORE II risk factor AVR MVR DVR CABG + AVR CABG + MVR
N 137 247 86 49 57
Age
 Mean ± SD 47.98 ± 16.3 43.08 ± 14.17 41.59 ± 13.4 60 ± 11.86 59.8 ± 10.77
 Female 29.2 60.3 43 22.4 38.6
Renal
 CC 50-85 43.1 44.9 44.2 45.9 33.3
 CC ≤50 10.2 9.7 7 14.3 38.5
 Chronic pulmonary disease 2.2 2.8 1.2 2 7
 Extra cardiac arteriopathy 1.5 0.4 0 0 0
 Insulin-dependent diabetes 3 3.2 1.4 8.2 14
 Neurological dysfunction 3 5.3 7 6.2 3.6
 Poor mobility 17.5 16.2 10.5 10.2 21.1
 Active endocarditis 6.6 4.9 10.5 0 0
 Previous cardiac surgery 5.8 13 12.8 12.2 7
 Critical preoperative condition 6.6 8.9 4.7 10.2 17.5
 Unstable angina 1.5 0 2.3 10.2 8.8
Left ventricular ejection fraction
 Moderate (31-50%) 19.7 12.6 22.1 24.5 38.6
 Poor (21-30%) 8 0.4 3.5 6.1 5.3
 Very poor (≤20%) 2.9 1.2 0 8.2 14
NYHA (%)
 I 26.3 26.3 26.7 8.2 7
 II 35.8 38.1 47.7 42.9 40.4
 III 20.4 19.4 15.1 40.8 33.3
 IV 17.5 16.2 10.5 8.2 19.3
CCS-4 3.6 4 5.8 16.3 21.1
Recent myocardial infarct 5.1 1.6 2.3 24.5 50.9
AVR = aortic valve replacement; CABG = coronary artery bypass grafting; DVR = double valve replacement; MVR = mitral valve replacement; NYHA = New York 
Heart Association; CC = creatinine clearance; CCS = Canadian Cardiovascular Society Score.
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TABLE II - Performance of risk models in patient subsets
Data set No. of 
Patients
Actual AES LES EuroSCORE II STS
Predicted ROC H-L  
p value
Predicted ROC H-L  
p value
Predicted ROC H-L  
p value
Predicted ROC H-L  
p value
All 576 4.86 5.16 0.819 0.184 6.96 0.819 0.233 4.94 0.816 0.552 2.13 0.812 0.290
MVR 247 2.83 4.40 0.881 0.335 5.46 0.877 0.495 3.12 0.898 0.689 1.87 0.882 0.319
AVR 137 2.91 4.44 0.721 0.390 4.93 0.722 0.634 2.49 0.747 0.660 1.29 0.635 0.116
DVR 86 2.32 3.98 0.619 0.431 4.09 0.699 0.371 2.76 0.637 0.346 – – –
CABG + MVR 57 1.84 9.30 0.755 0.726 17.30 0.736 0.756 18.22 0.773 0.133 4.84 0.657 0.884
CABG + AVR 49 1.88 8.26 0.587 0.156 13.12 0.581 0.102 9.36 0.521 0.118 2.64 0.775 0.480
AES = additive EuroSCORE; AVR = aortic valve replacement; CABG = coronary artery bypass grafting; DVR = double valve replacement; LES = logistic EuroSCORE; 
MVR = mitral valve replacement; ROC = receiver operating characteristic; STS = Society of Thoracic Surgeons (STS).
Fig. 1 - Receiver operating characteristic curves. A) Entire patient population (576 patients). B) MVR patients. C) AVR patients. 
D) CABG + MVR patients. E) CABG + AVR patients. F) DVR patients. G) STS ROC for entire patient population (490 patients excluding 
DVR cases).
ents the distribution of preoperative risk variables identified 
in our population. Majority of the patients (66.67%) under-
went single valve replacement.
There were a total of 28 deaths among 576 operated 
patients. The actual mortality rate of 4.86% was lower than 
5.16%, 6.96% and 4.94% predicted by AES, LES, EuroSCORE II, 
respectively, but was higher than 2.13% predicted by the STS 
scoring system. Table II shows the predictive ability, calibra-
tion and discriminatory power for all the risk stratifying algo-
rithms. As shown in Figure 1, all the models had good discrim-
inatory power (ROC >0.8) in the global patient sample ranging 
from 0.812 to 0.819. However, EuroSCORE II was better cali-
brated with highest Hosmer and Lemmeshow p value (0.552). 
Table III shows the performance of risk models in quintiles of 
risk. It shows EuroSCORE II overestimated mortality up to the 
5th decile and thereafter under predicted mortality. However, 
the difference in actual and predicted mortalities was less as 
compared to differences with AES and LES estimates.
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For patients undergoing single valve replacement, there 
was a general trend of overestimation by AES, LES and 
EuroSCORE II, while STS predicted mortality was lower than 
the actual value. A total of 14.9% patients had DVR. STS risk 
score does not code for DVR procedures and was henceforth 
not used in this comparison. In this subgroup, EuroSCORE II 
estimates were closest to actual mortality with AES and LES 
both overestimating mortality. Interestingly the actual mor-
tality paradoxically decreased in patients undergoing DVR 
as compared to single valve replacement, but the predicted 
mortality increased as expected. A total of 106 patients un-
derwent mitral valve replacement or AVR along with con-
comitant CABG surgery, with observed mortality being 1.88% 
and 1.84%, respectively. Although ROC and H-L p values were 
lower than those for single valve replacement procedures, 
when compared with the other three models, STS came out 
to be the best risk stratifying algorithm for valve replacement 
surgeries along with bypass.
Discussion
External validation of a risk-predicting model seeks to 
verify whether it can be generalized outside the boundaries 
of the population it was built upon, as a preliminary to using 
it as a reference for quality assessment (8). Differences in the 
clinical profile of reference population and the testing sample 
are generally considered as a serious hindrance to such a vali-
dation process. In addition, currently used risk score systems 
have been developed for quite some time and therefore re-
quire periodic recalibration and validation to reflect improved 
surgical techniques and postoperative patient management 
advances which occurred in recent times (9, 10).
Clinical profile of patients is quite different in Asia as op-
posed to the Western world. The difference lies in the differ-
ences of patient demographics; delayed clinical presentation 
due to socioeconomic, cultural and geographical reasons; in-
equitable distribution of medical facilities and different treat-
ment patterns (11). Similar differences combined with altered 
risk-adjusted mortality were also found in China and India 
when compared with that of STS and EuroSCORE II sample 
population (10, 12). The prevalence of rheumatic heart dis-
ease (RHD) has fallen drastically in developed countries, with 
VHD being a disease of the elderly only. On the contrary, prev-
alence of RHD in Pakistan has remained unchanged from 6 in 
1000 in the 1970s to 5.7 in 1000 in 2004 (13). Moreover, Rizvi 
et al (13) showed that less than 20% of those found to have 
RHD were aware of their diagnosis before participation in the 
study and only 8% of affected people (8%) were taking rheu-
matic prophylaxis. Secondly, we also had a higher incidence 
of active endocarditis (5.4%) compared to 2.2% in EuroSCORE 
II population. This may have led to the need for valve replace-
ment at a younger age in our patients. Mean age was 47.4 
years as compared to 64.6 years in EuroSCORE II patients 
(14). About 67.4% of patients in our study were <55 years of 
age and only 3.8% were above 75 years, compared to 25.6% 
<55 years and 27.5% above 75 years in the STS database.
Recently the role of EuroSCORE and STS has been ques-
tioned. In fact, several papers have suggested that these algo-
rithms may be no more adequate for risk estimation due to a 
two to threefold overestimation of the adult cardiac surgical 
risk. The lack of performance has been especially observed in 
valvular surgical subgroups because these models were devel-
oped and validated in a surgical population mainly composed 
of CABG. EuroSCORE II has been recently published to improve 
on the older EuroSCORE. In the EuroSCORE II more attention 
was given on the weight of surgical procedures in order to 
ameliorate the risk estimation even in non-CABG procedures 
although the core of risk factors is almost the same (14).
Since publication, the EuroSCORE II has been validated in 
large, European, multicenter cohorts. Grant et al (15) found 
that the performance of the tool was “more than satisfactory,” 
and well calibrated for a large proportion of patients. Barili et 
al (16) demonstrated that the EuroSCORE II is a good predic-
tor of perioperative mortality in isolated aortic valve surgery, 
with lower discrimination when compared with STS and a bet-
ter calibration when compared with LES, Age, creatinine and 
left ventricular ejection fraction model (ACEF) and STS scores. 
Its performance is optimal in the lowest tertile of patients, 
whereas it underpredicts mortality afterward. Overall, Euro-
SCORE II has better performance although it does not seem 
to significantly improve the performance of older EuroSCORE 
versions in the higher tertiles of risk. Although high-risk cases 
constitute only a small proportion of databases from which 
risk scores are elaborated and validated, they also express a 
significant proportion of the overall mortality, for which poor 
approximation in stratification cannot be easily tolerated. In 
this study, by applying both models on the surgical operation 
types (Tab. II), no statistically significant differences were ob-
served comparing AUC-AES, AUC-LES with AUC-EuroSCORE II 
(AUC = Area under the curve). However, EuroSCORE II was 
better calibrated than the older version. The worst discrimi-
nation of all three models was observed in the patients with 
combined valve and coronary surgery. Similar to our study, 
Carnero-Alcázar et al also found that EuroSCORE showed ex-
cellent discriminative capacity that has been slightly improved 
with the new EuroSCORE II version (17).
Few studies have drawn head to head comparison of STS 
and EuroSCORE II (12, 18, 19). Consistent with our findings, 
Wang et al (19) found that compared with the EuroSCORE II, 
the STS score gives an accurate prediction for individual op-
erative risk in patients undergoing heart valve surgery with 
concomitant CABG. Contrary to this, Kirmani et al (20) con-
cluded that EuroSCORE II and STS both provide equivalent 
discrimination (area under ROC EuroSCORE II vs. STS, 0.816 
vs. 0.810, p = 0.714) in predicting mortality in all cardiac sur-
gical procedures. However, STS risk values can be calculated 
only for selected procedures. In a recent study from India, 
large proportion of patients undergoing cardiac surgery had 
to be excluded because STS does not code for DVR, concomi-
tant tricuspid valve surgery or MAZE procedure (12). In our 
study, we had to exclude 14.9% patients from analysis who 
underwent surgeries for which STS risk score was not avail-
able. Our study showed STS to be well calibrated and showing 
high discrimination power for CABG and valve replacement 
patients.
There are several limitations to our study. First, our study is 
based on a relatively small sample size of patients from a single 
center, and so the truth of the performance of four risk mod-
els for predicting operative mortality in heart valve surgery in 
Pakistan could be biased, thus the results need to be further 
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examined using a large number of patients across the multi-
center database. Second, this is a retrospective investigation 
and deviation, such as ignoring a strong predictor (pulmonary 
hypertension), may weaken the results of the validation proce-
dure. Third, we examined all-cause mortality and were unable 
to determine the cause of death (cardiac or noncardiac). How-
ever, prediction of all-cause mortality is probably more practi-
cal than cardiac death alone.
The main results of our study are that (i) EuroSCORE II is 
the best predictor of mortality in isolated valve surgery pa-
tients (including both single valve replacements and DVRs). 
(ii) STS risk prediction algorithm is better calibrated for CABG + 
valve replacement. (iii) Clinical profile of Pakistani patients 
undergoing valvular surgery is uniquely different from Euro-
pean or American population where these risk models were 
developed and validated.
Conclusion
In conclusion, the EuroSCORE II gives an accurate pre-
diction for individual operative risk in patients undergoing 
isolated valve surgery, whereas STS performs better in the 
valve plus CABG group.
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